Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan

Lo C.-C.Huang C.-F.Cheng P.-N.Tseng K.-C.Chen C.-Y.Kuo H.-T.Huang Y.-H.Tai C.-M.Peng C.-Y.Bair M.-J.Chen C.-H.Yeh M.-L.Lin C.-L.Lin C.-Y.Lee P.-L.Chong L.-W.Hung C.-H.Chang T.S.Huang J.-F.Yang C.-C.Hu J.-T.Lin C.-W.Chen C.-T.Wang C.-C.Su W.-W.Hsieh T.-Y.Lin C.-L.Tsai W.-L.Lee T.-H.Chen G.-Y.Wang S.-J.Chang C.-C.Mo L.-R.Yang S.-S.Wu W.-C.Huang C.-S.Hsiung C.-K.Kao C.-N.Tsai P.-C.CHEN-HUA LIULee M.-H.CHUN-JEN LIUDai C.-Y.Chuang W.-L.Lin H.-C.JIA-HORNG KAOYu M.-L.TACR investigators2022-09-092022-09-0920220929-6646https://www.scopus.com/inward/record.uri?eid=2-s2.0-85123986584&doi=10.1016%2fj.jfma.2022.01.012&partnerID=40&md5=8570e22c4bb1bfea1ff5847048f279ebhttps://scholars.lib.ntu.edu.tw/handle/123456789/619187Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwanjournal article10.1016/j.jfma.2022.01.012351238492-s2.0-85123986584